Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration

Journal of Controlled Release

Volumn 213, Issue , 2015, Pages 112-119

  Horiguchi, Michiko ^a   Oiso, Yuki ^a   Sakai, Hitomi ^a   Motomura, Tomoki ^a   Yamashita, Chikamasa ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Akt; Alveolar regeneration; Chronic obstructive pulmonary disease (COPD); Phosphoinositide 3 kinase (PI3K); Wortmannin

Indexed keywords

DISEASES; MAMMALS; PHOSPHORYLATION; STEM CELLS; TISSUE;

AKT; ALVEOLAR REGENERATION; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; PHOSPHOINOSITIDE 3-KINASE; WORTMANNIN;

PULMONARY DISEASES;

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; AQUAPORIN 5; ELASTASE; EOSIN; HEMATOXYLIN; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PROTEIN KINASE B; SURFACTANT PROTEIN A; UNCLASSIFIED DRUG; WORTMANNIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-QUINOXALIN-6-YLMETHYLENETHIAZOLIDINE-2,4-DIONE; ANDROSTANE DERIVATIVE; HYDRAZONE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL RESPIRATORY DISEASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; INTRAPULMONARY DRUG ADMINISTRATION; LUNG ALVEOLUS EPITHELIUM CELL; LUNG COMPLIANCE; LUNG INJURY; LUNG PARENCHYMA; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURFACE TENSION; WEIGHT CHANGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG; LUNG ALVEOLUS; PATHOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGENERATION; STEM CELL;

ANDROSTADIENES; ANIMALS; CELL DIFFERENTIATION; CELL LINE; HUMANS; HYDRAZONES; LUNG; MALE; MICE, INBRED ICR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOXALINES; REGENERATION; STEM CELLS; SULFONAMIDES; THIAZOLIDINEDIONES;

EID: 84936858746     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.07.004     Document Type: Article

References (22)

1. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, and J. Zielinski Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am. J. Respir. Crit. Care Med. 176 2007 532 555
2. A. Giangreco, E.N. Arwert, I.R. Rosewell, J. Snyder, F.M. Watt, and B.R. Stripp Stem cells are dispensable for lung homeostasis but restore airways after injury Proc. Natl. Acad. Sci. U. S. A. 106 2009 9286 9291
3. J.R. Rock, M.W. Onaitis, E.L. Rawlins, Y. Lu, C.P. Clark, Y. Xue, S.H. Randell, and B.L. Hogan Basal cells as stem cells of the mouse trachea and human airway epithelium Proc. Natl. Acad. Sci. U. S. A. 106 2009 12771 12775
4. I.Y. Adamson, and D.H. Bowden The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen Lab. Invest. 30 1974 35 42
5. M.J. Evans, L.J. Cabral, R.J. Stephens, and G. Freeman Transformation of alveolar type 2 cells to type 1 cells following exposure to NO2 Exp. Mol. Pathol. 22 1975 142 150
6. J. Wang, K. Edeen, R. Manzer, Y. Chang, S. Wang, X. Chen, C.J. Funk, G.P. Cosgrove, X. Fang, and R.J. Mason Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro Am. J. Respir. Cell Mol. Biol. 36 2007 661 668
7. N. Fujino, H. Kubo, T. Suzuki, C. Ota, A.E. Hegab, M. He, S. Suzuki, M. Yamada, T. Kondo, H. Kato, and M. Yamaya Isolation of alveolar epithelial type II progenitor cells from adult human lungs Lab. Invest. 91 2011 363 378
8. M. Horiguchi, H. Kojima, H. Sakai, H. Kubo, and C. Yamashita Pulmonary administration of integrin-nanoparticles regenerates collapsed alveoli J. Control. Release 187C 2014 167 174
9. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 7 2006 606 619
10. P.T. Hawkins, and L.R. Stephens PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis Science 318 2007 64 66
11. T. Sasaki, J. Irie-Sasaki, R.G. Jones, A.J. Oliveira-dos-Santos, W.L. Stanford, B. Bolon, A. Wakeham, A. Itie, D. Bouchard, I. Kozieradzki, N. Joza, T.W. Mak, P.S. Ohashi, A. Suzuki, and J.M. Penninger Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration Science 287 2000 1040 1046
12. J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, W. Wrasidlo, L.M. Acevedo, and D.A. Cheresh Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease J. Pharmacol. Exp. Ther. 328 2009 758 765
13. K. Tanaka, T. Ishihara, T. Sugizaki, D. Kobayashi, Y. Yamashita, K. Tahara, N. Yamakawa, K. Iijima, K. Mogushi, H. Tanaka, K. Sato, H. Suzuki, and T. Mizushima Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease Nat. Commun. 4 2013 2686
14. X. Liu, A.M. Das, J. Seideman, D. Griswold, C.N. Afuh, T. Kobayashi, S. Abe, Q. Fang, M. Hashimoto, H. Kim, X. Wang, L. Shen, S. Kawasaki, and S.I. Rennard The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6 Am. J. Respir. Cell Mol. Biol. 37 2007 121 128
15. J. Azzi, R.F. Moore, W. Elyaman, M. Mounayar, N. El Haddad, S. Yang, M. Jurewicz, A. Takakura, A. Petrelli, P. Fiorina, T. Ruckle, and R. Abdi The novel therapeutic effect of phosphoinositide 3-kinase-gamma inhibitor AS605240 in autoimmune diabetes Diabetes 61 2012 1509 1518
16. N.M. Dagia, G. Agarwal, D.V. Kamath, A. Chetrapal-Kunwar, R.D. Gupte, M.G. Jadhav, S.S. Dadarkar, J. Trivedi, A.A. Kulkarni-Almeida, F. Kharas, L.C. Fonseca, S. Kumar, and M.R. Bhonde A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner Am. J. Physiol. Cell Physiol. 298 2010 C929 C941
17. N. Fujino, C. Ota, T. Suzuki, S. Suzuki, A.E. Hegab, M. Yamada, T. Takahashi, M. He, T. Kondo, H. Kato, M. Yamaya, and H. Kubo Analysis of gene expression profiles in alveolar epithelial type II-like cells differentiated from human alveolar epithelial progenitor cells Respir. Invest. 50 2012 110 116
18. T.V. Burdyga, and S. Wray The effect of inhibition of myosin light chain kinase by wortmannin on intracellular [Ca2 +], electrical activity and force in phasic smooth muscle Pflugers Arch. 436 1998 801 803
19. C. Dall'Armi, A. Hurtado-Lorenzo, H. Tian, E. Morel, A. Nezu, R.B. Chan, W.H. Yu, K.S. Robinson, O. Yeku, S.A. Small, K. Duff, M.A. Frohman, M.R. Wenk, A. Yamamoto, and G. Di Paolo The phospholipase D1 pathway modulates macroautophagy Nat. Commun. 1 2010 142
20. S.D. Sorensen, D.A. Linseman, E.L. McEwen, A.M. Heacock, and S.K. Fisher A role for a Wortmannin-sensitive phosphatidylinositol-4-kinase in the endocytosis of muscarinic cholinergic receptors Mol. Pharmacol. 53 1998 827 836
21. H. Yano, S. Nakanishi, K. Kimura, N. Hanai, Y. Saitoh, Y. Fukui, Y. Nonomura, and Y. Matsuda Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells J. Biol. Chem. 268 1993 25846 25856
22. D.A. Fruman, and C. Rommel PI3K and cancer: lessons, challenges and opportunities Nat. Rev. Drug Discov. 13 2014 140 156